Point your AI agent at freehire and let it find you a job.

Get the CLI →

sequel-med-tech

Develops automated insulin delivery systems for personalized diabetes management.

Discussion
health-techhealthcaremedical-devicespharmaceuticals

Company facts

Founded
2023
Employees
350
Headquarters
United States
CEO
Alan Lotvin, MD
Type
Private
Funding
Seed · $5M · 2021
Subsidiaries
SequelConnect

About

Sequel is Changing the Future of Diabetes Management. Around 63% of people with diabetes requiring insulin therapy are currently not using AID systems, a result of challenges that still exist in delivering optimal diabetes care. Sequel removes the barriers for accessible revolutionary insulin therapy, so more people with diabetes can improve their health and wellbeing. Simplified Access is at the forefront of Sequel, delivering the most affordable automated insulin delivery (AID) system through pharmacy channels. The technology is designed for everyday wear with precise measurement technology to help ensure accurate insulin delivery. Additionally, Sequel's personalized control automatically adjusts insulin delivery and is powered by the Tidepool algorithm, demonstrating real-world evidence of clinically meaningful benefits. Sequel is not stopping at revolutionary Type One Diabetes technology but continues to provide extraordinary support in advancing diabetes care. They serve diverse groups including healthcare providers, employers, consultants, and pharmaceutical companies, transforming how people with diabetes access and manage their condition.

Tailor your CV for this role?

We couldn't check your fit for this role — add a CV to your profile to see it next time.